We studied the possibility of inhibition of histone deacetylases (HDAC) in the nuclear extract of HeLa cells by N1-hydroxy-N4-(pyridin-4-yl)succinamide (compound 1). Compound 1 inhibits HDAC and showed low toxicity for A-172, HepG2, HeLa, MCF-7, and Vero cells. HeLa cells were most sensitive to the compound. Increasing the interval between administration of compound 1 and the chemotherapeutic agent to 8 h led to an increase in the cytotoxic effect of cisplatin (actinomycin D) on HeLa cells. The combination of compound 1 with cisplatin (actinomycin D) reduced the cytotoxic effect of these drugs for non-tumor Vero cells.
Similar content being viewed by others
References
Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH, Nam JH. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J. Gynecol. Oncol. 2010;21(4):262-268. https://doi.org/10.3802/jgo.2010.21.4.262
Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504. https://doi.org/10.1016/j.lfs.2021.119504
Kulinchik TV. Cisplatin: discovery of antitumor activity. Med. Tekhnol. Otsenka Vybor. 2013;(1):87-90. Russian.
Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008;6(1):1-18. https://doi.org/10.1111/j.1476-5829.2007.00142.x
Lamture G, Crooks PA, Borrelli MJ. Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells. Drug Dev. Res. 2018;79(6):287-294. https://doi.org/10.1002/ddr.21441
Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front. Genet. 2020;11:578011. https://doi.org/10.3389/fgene.2020.578011
Yu L, Liu F, Chen Y, You Q. Pharmacophore identification of hydroxamate HDAC 1 inhibitors. Chin. J. Chem. 2009;27(3):557-564. https://doi.org/10.1002/cjoc.200990091
Tretyakov BA, Gadomskij SYa, Luzhkov VB, Terentev AA. Patent RU No. 2769320. Method for producing derivatives of N-hydroxybutanamide. Bull. No. 10. Published March 30, 2022.
Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl Acad. Sci. USA. 1989;86(7):2336-2340. https://doi.org/10.1073/pnas.86.7.2336
Mosmann T. Rapid colorimetric assay for cellular growth and survivals: application to proliferation and cytotoxity assay. J. Immunol. Methods. 1983;65(1-2):55-63. https://doi.org/10.1016/0022-1759(83)90303-4
Tóth KF, Knoch TA, Wachsmuth M, Frank-Stöhr M, Stöhr M, Bacher CP, Müller G, Rippe K. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J. Cell Sci. 2004;117(Pt 18):4277-4287. https://doi.org/10.1242/jcs.01293
Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin. Transl. Oncol. 2008;10(7):395-398. https://doi.org/10.1007/s12094-008-0221-x
Reichling J, Schnitzler P, Suschke U, Saller R. Essential oils of aromatic plants with antibacterial, antifungal, antiviral, and cytotoxic properties — an overview. Forsch. Komplementmed. 2009;16(2):79-90. https://doi.org/10.1159/000207196
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 175, No. 1, pp. 29-33, January, 2023
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tretyakov, B.A., Filatova, N.V., Mumyatova, V.A. et al. Pyridine Derivative of Succinic Acid Hydroxylamide Enhances the Cytotoxic Effect of Cisplatin and Actinomycin D. Bull Exp Biol Med 175, 23–26 (2023). https://doi.org/10.1007/s10517-023-05803-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-023-05803-4